- Home
- NOV vs RYTM Comparison
NOV vs RYTM Comparison
Compare NOV & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOV | RYTM |
|---|---|---|
| Founded | 1862 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.4B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NOV | RYTM |
|---|---|---|
| Price | $16.36 | $113.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $15.69 | ★ $125.77 |
| AVG Volume (30 Days) | ★ 3.5M | 833.9K |
| Earning Date | 10-27-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $8,775,000,000.00 | $174,334,000.00 |
| Revenue This Year | N/A | $47.34 |
| Revenue Next Year | N/A | $57.18 |
| P/E Ratio | $16.45 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $10.84 | $45.91 |
| 52 Week High | $16.96 | $122.20 |
Technical Indicators
Market Signals| Indicator | NOV | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 61.98 | 59.90 |
| Support Level | $15.88 | $99.96 |
| Resistance Level | $16.96 | $122.20 |
| Average True Range (ATR) | 0.45 | 5.28 |
| MACD | 0.05 | 1.05 |
| Stochastic Oscillator | 73.73 | 61.92 |
Price Performance
Historical ComparisonAbout NOV NOV Inc.
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.